Contrasting Longevity Health (XAGE) and Its Competitors
by Scott Moore · The Cerbat GemProfitability
This table compares Longevity Health and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longevity Health | -682.67% | N/A | -261.90% |
| Longevity Health Competitors | -570.12% | -153.34% | -54.42% |
Institutional and Insider Ownership
24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 29.0% of Longevity Health shares are owned by insiders. Comparatively, 19.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Longevity Health and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Longevity Health | $1.05 million | -$10.37 million | -0.07 |
| Longevity Health Competitors | $60.44 million | -$32.15 million | 5.33 |
Longevity Health’s peers have higher revenue, but lower earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Longevity Health has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Longevity Health’s peers have a beta of 1.76, meaning that their average stock price is 76% more volatile than the S&P 500.
Summary
Longevity Health peers beat Longevity Health on 5 of the 9 factors compared.
Longevity Health Company Profile
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.